Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. Issue 6 (2nd May 2022)
- Record Type:
- Journal Article
- Title:
- Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. Issue 6 (2nd May 2022)
- Main Title:
- Super enhancer‐LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1
- Authors:
- Shen, Qiang
Zhou, Huixin
Zhang, Meijuan
Wu, Ruihao
Wang, Liangxing
Wang, Yumin
Chen, Jie - Abstract:
- Abstract: Background: Super enhancer‐lncRNA smooth muscle and endothelial cell‐enriched migration/differentiation‐associated lncRNA (SENCR) were highly overexpressed in cisplatin‐resistant A549/DDP cells, while the mechanism was unclear. Methods: SE‐lncRNA SENCR and FLI1 mRNA expression in A549/DDP cell, LAD tissues were detected. SENCR knockdown of A549/DDP cell and SENCR overexpression of cisplatin‐sensitive A549 cell were constructed. Experiments of cell‐confirmed function of SENCR and the correlation between SENCR and FLI1 were validated. Results: The expression of SENCR and FLI1 mRNA in A549/DDP cell were both upregulated and mainly localized in the nucleus. Compared with DDP‐sensitive tissues with disease relief, SENCR expression was higher in DDP‐resistant tissues with disease progression from LAD. Knockdown of SENCR in A549/DDP reduced proliferation ability and cisplatin resistance, consistent with the decreased levels of proteins PCNA, MDMX, and P‐gp. Besides, whatever without cisplatin or with 2 μg/ml cisplatin, knockdown of SENCR reduced the migration, invasion, and colony formation abilities of A549/DDP cell and promoted apoptosis. However, when SENCR was overexpressed in A549 cell, all above results were reversed. Mechanistically, FLI1 expression was reduced after knocking down SENCR, while overexpressing SENCR increased FLI1 expression. Conclusion: SE‐LncRNA SENCR was upregulated in A549/DDP, which could promote cisplatin resistance and growth of NSCLC cellAbstract: Background: Super enhancer‐lncRNA smooth muscle and endothelial cell‐enriched migration/differentiation‐associated lncRNA (SENCR) were highly overexpressed in cisplatin‐resistant A549/DDP cells, while the mechanism was unclear. Methods: SE‐lncRNA SENCR and FLI1 mRNA expression in A549/DDP cell, LAD tissues were detected. SENCR knockdown of A549/DDP cell and SENCR overexpression of cisplatin‐sensitive A549 cell were constructed. Experiments of cell‐confirmed function of SENCR and the correlation between SENCR and FLI1 were validated. Results: The expression of SENCR and FLI1 mRNA in A549/DDP cell were both upregulated and mainly localized in the nucleus. Compared with DDP‐sensitive tissues with disease relief, SENCR expression was higher in DDP‐resistant tissues with disease progression from LAD. Knockdown of SENCR in A549/DDP reduced proliferation ability and cisplatin resistance, consistent with the decreased levels of proteins PCNA, MDMX, and P‐gp. Besides, whatever without cisplatin or with 2 μg/ml cisplatin, knockdown of SENCR reduced the migration, invasion, and colony formation abilities of A549/DDP cell and promoted apoptosis. However, when SENCR was overexpressed in A549 cell, all above results were reversed. Mechanistically, FLI1 expression was reduced after knocking down SENCR, while overexpressing SENCR increased FLI1 expression. Conclusion: SE‐LncRNA SENCR was upregulated in A549/DDP, which could promote cisplatin resistance and growth of NSCLC cell through upregulating FLI1 expression. Abstract : Knockdown of SENCR in A549/DDP reduced proliferation ability and cisplatin resistance, the migration, invasion, and colony formation abilities of A549/DDP cell and promoted apoptosis. SE‐LncRNA SENCR was highly expressed in A549/DDP, which could promote the growth and cisplatin resistance of NSCLC cell through the positive correlation of FLI1 expression. … (more)
- Is Part Of:
- Journal of clinical laboratory analysis. Volume 36:Issue 6(2022)
- Journal:
- Journal of clinical laboratory analysis
- Issue:
- Volume 36:Issue 6(2022)
- Issue Display:
- Volume 36, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 36
- Issue:
- 6
- Issue Sort Value:
- 2022-0036-0006-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-05-02
- Subjects:
- cisplatin resistance -- non‐small cell lung cancer -- smooth muscle and endothelial cell enriched migration/differentiation‐associated lncRNA -- super enhancer‐lncRNA
Diagnosis, Laboratory -- Periodicals
Medical laboratory technology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/jcla.24460 ↗
- Languages:
- English
- ISSNs:
- 0887-8013
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.520000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21854.xml